Peter Michener YOU? Author Swipe

Last 10y

<span>DNA</span> fork remodeling proteins, Zranb3 and Smarcal1, are uniquely essential for aging hematopoiesis Open

Saul Kushinsky, Matthew V. Puccetti, Clare M. Adams, Irina Shkundina, N. Ingle James , et al. · 2024

Over a lifetime, hematopoietic stem and progenitor cells (HSPCs) are forced to repeatedly proliferate to maintain hematopoiesis, increasing their susceptibility to DNA damaging replication stress. However, the proteins that mitigate this s…

Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma Open

Clare M. Adams, Amanda McBride, Peter Michener, Irina Shkundina, Ramkrishna Mitra , et al. · 2024

Clinical trials with single-agent venetoclax/ABT-199 (anti-apoptotic BCL2 inhibitor) revealed that diffuse large B-cell lymphoma (DLBCL) is not solely dependent on BCL2 for survival. Gaining insight into pathways/proteins that increase ven…

Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chi…

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chi…

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chi…

Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chi…

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7

Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chi…

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Open

Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo , et al. · 2023

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chi…

Fetching topic information...